您要查找的是不是:
- Antiplatelet therapy is recommended for symptomatic patients. 推荐抗血小板治疗症状性患者。
- Antiplatelet Therapy for Secondary Prevention of Cardiovascular Events: More "Advanced" Drug, More Perfect? 心血管事件的二级预防:抗血小板治疗药物越“先进”越完美吗?
- The FDA also recommends prolonged dual antiplatelet therapy for at least a year following the intervention. FDA也推荐介入治疗后至少延长一年对病人进行双重抗血小板治疗。
- The status of antiplatelet therapy at the time of ST was known for most patients. 已知大多数患者ST发生时抗血小板治疗的情况。
- The authors recommended that intensified antiplatelet therapy might be indicated for type 2 diabetic patients. 作者建议强化抗血小板疗法可能会用于2型糖尿病患者。
- The report makes a number of practical recommendations to eliminate early discontinuation of antiplatelet therapy. 这个报道列出了多条实用的建议来减少早期停用抗血小板治疗。
- In the future, antiplatelet therapy will likely be tailored for the indiidual patient, they note. 他们指出:抗血小板治疗将来可能只会针对个别病人。
- The FDA also recommends prolonged dual antiplatelet therapy for at least a year following the interention. FDA也推荐介入治疗后至少延长一年对病人进行双重抗血小板治疗。
- It is well recognized that antiplatelet therapy is effective in the prevention and treatment of thrombosis. 摘要抗血小板治疗可以有效预防和治疗血栓性疾病,氯吡格雷是一种新型安全高效的抗血小板药物。
- The antiplatelet regimen for standard group was dual antiplatelet therapy with aspirin and clopidogrel. 标准组所有病例均采用标准阿司匹林、氯吡格雷两联抗血小板治疗;
- Warfarin is substantially more efficacious (by approximately 40%) than antiplatelet therapy. 而实际上,华法林比抗血小板治疗更加有效(大约40%25)。
- A Comparison of Dual vs. Triple Antiplatelet Therapy in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome: Results of the ELISA-2 Trial. 非ST段抬高急性冠脉综合征患者双重与三重抗血小板治疗的比较:ELISA-2试验的结果。
- These improvements are likely a result of increased use of clopidogrel, statins, and dual antiplatelet therapy, in addition to the introduction of DES. 这些改善,除了引进的DES,有可能导致更多地使用氯吡格雷,他汀类,以及双抗血小板治疗。
- It has been suggested that antiplatelet therapy may preent thrombotic eents contributing to subclinical CAD progression, the researchers explain. 研究人员解释道,“已有研究表明,抗血小板治疗能预防血栓事件,促成亚临床CAD的进展。”
- DES recipients had longer and more complex lesions than BMS recipients and also were more likely to be receiving dual antiplatelet therapy at 1 year. 接受药物洗脱支架的患者长病变和复杂病变比接受裸金属支架的患者多,而且接受双重抗血小板治疗1年的可能性较大。
- Can the problem of late drug-eluting stent thrombosis be solved by the novel recommendation to extend dual antiplatelet therapy to 12 months? 如果依据最新建议将抗血小板凝集药物延长服用至12个月是否能够解决涂药支架血栓的问题?
- In this prospective, monocentric study, 17 PCFPs in 16 patients were embolized during anticoagulant or antiplatelet therapy. 在预期的单中心研究中,在运用抗凝血剂或抗血小板治疗期间,给16个病人实施的17次PCFP治疗发生了栓塞。
- Objective To explore the feasibility and efficacy of an optimized antiplatelet therapy according to laboratory test after coronary stenting. 摘要目的探讨根据实验室检测结果调整、优化冠状动脉支架术后抗血小板治疗方案的可行性和有效性。
- In optimal group, CR patients received cilostazol for 6 months in addition to dual anitplatelet therapy, whereas non-CR patients received standard dual antiplatelet therapy. 优化组非CR患者接受标准两联抗血小板治疗,CR患者在标准两联治疗基础上加服西洛他唑6个月。
- The safe alternative antiplatelet agent for long administration should be used if aspirin resistance appears, prediction of AR and individualization of antiplatelet therapy would be an emerging direction of antiplatelet therapy. ASA用于抗血小板治疗及预防动脉硬化事件的脑血管病患者,若有AR存在,应及时换用其它安全有效的抗血小板制剂,因阿司匹林需要长期应用,今后预测AR及抗血小板治疗个体化,将是未来抗血小板治疗的研究方向。